Voting
Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing
866-314-3599.
2025 Annual Meeting
View an enhanced version of our Annual Report.
View an enhanced version of our Notice of Meeting & Proxy Statement.
Request paper copies of the proxy materials online now, by email or by phone by dialing 866-648-8133.
Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing
866-314-3599.
Register for our virtual meeting. You must register to be eligible to join the meeting.
DATE: August 12, 2025
TIME: 11:30 AM ET
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is currently being evaluated in an ongoing, Phase 1 clinical trial for the treatment of nAMD, with plans to develop TH103 for other neovascular and exudative diseases of the retina such as Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).